Free Newsletter
NIH researcher at center of new conflict controversy
A senior NIH researcher is at the center of a fresh round of charges regarding a potential conflict of interest between his financial interests and his research work. Charles Natanson penned an article in JAMA criticizing the safety risks presented by experimental blood substitutes. But he failed to mention that he is a co-inventor of a technology in development at NIH that may make the products safer.
That link drew a rebuke from executives at Biopure and Northfield, which have been struggling to obtain approvals for their products. Biopure CEO Zafiris Zafirelis called the research "seriously flawed." Natanson told the Wall Street Journal that the omission was an error of judgment and took responsibility for it. But he also added that he stands by the study's findings.
- read the story in the Wall Street Journal
Related Articles:
NIH researcher charged with conflict
NIH official implicated in scandal
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
